In addition, reduced food intake and decreased feelings of hunger were reported by the study participants over the following 24 hours
Cagrilintide development and structure What cagrilintide is: Synthetic long-acting amylin analog Modified 37-amino acid sequence Developed by Novo Nordisk Designed specifically for obesity treatment Based on natural amylin but optimized Key structural modifications: Amino acid substitutions for stability Prevented amyloid aggregation (major improvement) Extended half-life to ~7 days (vs minutes for natural amylin) Maintained receptor binding and activity Better pharmacokinetic profile Development timeline: Early 2010s: Initial development 2019-2020: Phase 2 trials (OASIS) 2021-2023: Phase 3 trials (REDEFINE as CagriSema) 2024-2025: FDA submission expected Likely approval 2025-2026 Why cagrilintide is breakthrough: First truly long-acting amylin agonist Weekly dosing (vs pramlintide 2-3x daily) Designed for weight loss (not diabetes adaptation) Proven synergy with semaglutide (CagriSema) Approaching availability Cagrilintide weight loss results Monotherapy clinical data (OASIS trials): Duration: 26-68 weeks Dose: 2.4mg weekly (standard) Average weight loss: 10-12% Some participants: 15%+ loss Well-tolerated at therapeutic dose Weight loss by dose: 0.6mg weekly: ~6% weight loss 1.2mg weekly: ~8% weight loss 2.4mg weekly: ~10% weight loss 4.5mg weekly: ~12% weight loss (higher side effects) CagriSema combination (cagrilintide + semaglutide): Both at 2.4mg weekly Average weight loss: 15.6% (REDEFINE-1) Excellent responders: 20-25% 50% more than semaglutide alone Game-changing results Real-world expectations: See our comprehensive cagrilintide weight loss guide
"Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology
It appears to work through multiple mechanisms, including enhanced angiogenesis (formation of new blood vessels), upregulation of growth hormone receptors, and modulation of nitric oxide pathways
Just like earlier forms of Ozempic, Zepbound, Mounjaro and Wegovy, study volunteers used injector pens to give themselves shots of retatrutide once a week
How to Prevent Hair Loss While Taking GLP-1 Inhibitors In recent years, GLP-1 inhibitors like semaglutide and liraglutide have gained widespread acclaim for their effectiveness in managing obesity and refining blood sugar levels
